13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001848809
Total reported value
$164.2M
$164.2M
17 檔
92.1%
At the close of Q2 2024, Velan Capital Investment Management LP disclosed equity holdings valued at approximately $164.2M, spread across 17 reported holdings.
During Q2 2024, Velan Capital Investment Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Alimera Sciences Inc | Stock-Other | 43.35% | — | — | |
| 2 | JSPR | Jasper Therapeutics Inc | Stock-Other | 18.65% | -0.78% | — | |
| 3 | HRTX | Heron Therapeutics Inc | Stock-Other | 14.01% | -2.11% | — | |
| 4 | PRAX | Praxis Precision Medicines I | Stock-Other | 8.31% | -2.24% | — | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 2.35% | — | — | |
| 6 | TELA | Tela Bio Inc | Stock-Other | 2.01% | — | — | |
| 7 | RZLT | Rezolute Inc | Stock-Other | 1.97% | +0.95% | +100.00% | |
| 8 | SKYE | Skye Bioscience Inc | Stock-Other | 1.94% | — | — | |
| 9 | ✓ | Optinose Inc | Stock-Other | 1.49% | — | -16.94% | |
| 10 | CNTX | Context Therapeutics Inc | Stock-Other | 1.48% | -0.14% | — | |
| 11 | NSPR | Inspiremd Inc | Stock-Other | 1.29% | -2.08% | — | |
| 12 | OTLK | Outlook Therapeutics Inc | Stock-Other | 1.04% | — | -50.58% | |
| 13 | ✓ | Elevation Oncology Inc | Stock-Other | 0.92% | — | +20.11% | |
| 14 | TARA | Protara Therapeutic Inc | Stock-Other | 0.57% | -2.63% | — | |
| 15 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.29% | — | — | |
| 16 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.22% | — | — | |
| 17 | ✓ | Aslan Pharmaceuticals LTD | Stock-Other | 0.11% | — | — |
According to official SEC Form 13F filings, Velan Capital Investment Management LP reported a total U.S. public equity portfolio value of $164.2M across 17 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ALIMERA SCIENCES INC, JSPR, HRTX) accounted for 92.1% of total reported equity market value during Q2 2024.
During Q2 2024, Velan Capital Investment Management LP's top holdings by market value included ALIMERA SCIENCES INC (43.4%)、JSPR (18.6%)、HRTX (14.0%). The largest single position, ALIMERA SCIENCES INC, represented 43.4% of total portfolio value.
In Q2 2024, Velan Capital Investment Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.